CAM
BHVN

Cormorant Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Cormorant Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-184,894
Closed -$27.9M – 81
2022
Q3 		$27.9M Hold
184,894
– – 1.95% 18
2022
Q2 		$26.9M Buy
184,894
+104,894
+131% +$13.4M 2.04% 18
2022
Q1 		$9.49M Buy
+80,000
New +$9.98M 0.73% 42
2021
Q2 		– Sell
-200,000
Closed -$13.7M – 135
2021
Q1 		$13.7M Sell
200,000
-225,000
-53% -$18.2M 0.3% 63
2020
Q4 		$36.4M Sell
425,000
-75,000
-15% -$6.36M 0.87% 32
2020
Q3 		$32.5M Sell
500,000
-100,000
-17% -$6.55M 1.25% 28
2020
Q2 		$43.9M Sell
600,000
-275,551
-31% -$14.7M 1.67% 21
2020
Q1 		$29.8M Sell
875,551
-124,449
-12% -$5.69M 1.38% 22
2019
Q4 		$54.4M Sell
1,000,000
-281,400
-22% -$13.9M 2.17% 14
2019
Q3 		$53.5M Sell
1,281,400
-268,600
-17% -$11.3M 3.25% 7
2019
Q2 		$67.9M Buy
1,550,000
+450,000
+41% +$25.4M 3.9% 7
2019
Q1 		$56.6M Buy
1,100,000
+450,000
+69% +$19.4M 3.83% 7
2018
Q4 		$24M Buy
650,000
+390,000
+150% +$14.1M 1.95% 15
2018
Q3 		$9.76M Sell
260,000
-24,735
-9% -$910K 0.63% 36
2018
Q2 		$11.3M Hold
284,735
– – 0.83% 36
2018
Q1 		$7.33M Sell
284,735
-13,068
-4% -$391K 0.55% 32
2017
Q4 		$8.04M Buy
+297,803
New +$8.2M 0.84% 30

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Cormorant Asset Management's BHVN Position: Q4 2022 in Review

Cormorant Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 184,894 shares — an estimated $27.9M sold.

Cormorant Asset Management first reported a position in BHVN in Q4 2017 and held it in 17 quarters. The position peaked at $67.9M in Q2 2019. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Cormorant Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Cormorant Asset Management sold 184,894 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $27.9M.
  • Cormorant Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 17 quarters.
  • Cormorant Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $67.9M in Q2 2019.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Cormorant Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.